**3D modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model**

Sarah L. Maguire1^, Barrie Peck1,2^, Patty T Wai1,2, James Campbell1,2, Holly Barker 1,2, Aditi Gulati1,2, Frances Daley1, Simon Vyse3, Paul Huang3, Christopher J Lord1,2, Gillian Farnie4, Keith Brennan5 and Rachael Natrajan1,2\*.

1The Breast Cancer Now Toby Robins Research Centre,Division of Breast Cancer, The Institute of Cancer Research, London UK

2Division of Molecular Pathology, The Institute of Cancer Research, London UK

3 Division of Cancer Biology, The Institute of Cancer Research, London UK

4 Institute of Cancer Sciences, University of Manchester, Wilmslow Road, Manchester, M20 4BX

5 Faculty of Life Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT

^**Equal contribution**

***\*Correspondence to:*** *Rachael C. Natrajan, PhD, The Breast Cancer Now Toby Robins Research Centre,**Mary-Jean Mitchell Green Building, The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP Email:* *rachael.natrajan@icr.ac.uk*

**Short running title:** Breast cancer progression in 2D and 3D systems

Raw whole genome, exome and RNA-sequencing data have been deposited into the NCBI Sequence Read Archive under the accession PRJNA308098.

**Conflict of interest:** The authors declare no conflict of interest.

**Word count:** 4431

**ABSTRACT**

The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma *in situ* (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations, changes in gene expression, alongside microenvironmental and recognised histological alterations. Here we sought to comprehensively characterise the genomic and transcriptomic features of the MCF10 isogenic model of breast cancer progression and to functionally validate potential driver alterations in 3-dimensional (3D) spheroids that may give insight into breast cancer progression and identify targetable alterations in conditions more similar to those encountered *in vivo*. We performed whole genome, exome and RNA sequencing of the MCF10 progression series to catalogue the copy number, mutational and transcriptomic landscapes associated with progression. We identified a number of predicted driver mutations (including *PIK3CA* and *TP53*) that were acquired from non-malignant MCF10A cells to their malignant counterparts that are also present in primary breast cancers re-analysed from The Cancer Genome Atlas (TCGA). Acquisition of genomic alterations identified *MYC* amplification and previously un-described *RAB3GAP1-HRAS* and *UBA2-PDCD2L* expressed in-frame fusion genes in malignant cells. Comparison of pathway aberrations associated with progression identified that when cells are grown as 3D spheroids, they show perturbations of cancer-relevant pathways. Functional interrogation of the dependency on predicted driver events, identified alterations in *HRAS*, *PIK3CA*, and *TP53* that selectively decreased cell growth and were associated with progression from pre-invasive to invasive disease, only when cells were grown as spheroids. Our results have identified changes in the genomic repertoire in cell lines representative of the stages of breast cancer progression and demonstrate that genetic dependencies can be uncovered when cells are grown in conditions more like *in vivo*. The MCF10 progression series, therefore, represents a good model to dissect potential biomarkers and evaluation of therapeutic targets involved in the progression of breast cancer.

**Keywords:** Breast cancer progression, 3D spheroid assays, next generation sequencing

**INTRODUCTION**

The initiation and progression of breast cancer from the transformation of the normal epithelium to carcinoma *in situ* and invasive disease is a multifaceted process that results in the acquisition of multiple genomic alterations, including changes in genomic copy number, structural rearrangements, acquisition of mutations as well as altered gene expression and pathway dysregulation [[1-4](#_ENREF_1)]. The transition through these states, i.e. non-invasive to invasive disease is a well-defined and staged process, through which breast cancers progress to procure the capacity to grow, persist and eventually spread to secondary sites.

High-throughput molecular profiling of breast cancers and their precursor lesions revealed that they display distinct genomic and transcriptomic alterations [[3](#_ENREF_3),[5-8](#_ENREF_5)], however, matched pre-invasive lesions and invasive counterparts from the same patient are remarkably similar [[6-10](#_ENREF_6)], suggesting that the extent of genomic heterogeneity is acquired early on in breast cancer development. There is evidence that suggests the progression from *in situ* to invasive disease is not exclusively driven by specific genomic aberrations in the pre-invasive cells but is a result of paracrine interactions of tumour cells with the surrounding stromal environment [[3](#_ENREF_3),[11-13](#_ENREF_11)].

The MCF10 progression series is a product of the ‘normal’ mammary epithelial cell line MCF10A that is spontaneously immortalised from the MCF10 mortal cell line (MCF10M), that originated from benign fibrocystic disease [[14](#_ENREF_14)]. As MCF10A cells are non-tumorigenic, cells were HRAS transformed to produce MCF10neoT and MCF10AT1 [[15](#_ENREF_15),[16](#_ENREF_16)] (Figure 1A). MCF10AT1 cells were subsequently serially passaged *in vivo* to produce carcinoma *in situ* MCF10DCIS.com [[17](#_ENREF_17)] and invasive carcinoma cells MCF10Ca1a, MCF10Ca1d and MCF10Ca1h [[18](#_ENREF_18),[19](#_ENREF_19)]. MCF10Ca1a and MCF10Ca1d are *in vitro* clones derived from the same *in vivo* tumour, whereas MCF10Ca1h is derived from a separate tumour (Figure 1A). This series of cell lines, therefore, represents an isogenic model of disease progression and provides a useful tool for the investigation of molecular changes during progression of human breast neoplasia and the generation of tumour heterogeneity on a common genetic background [[19](#_ENREF_19)].

Numerous studies have characterised different cell lines from the MCF10 progression series through genomic, transcriptomic and proteomic profiling [[20-26](#_ENREF_20)]. These have shown that alterations that differ between the cell lines can identify drivers of different stages of breast cancer progression. Indeed, proteomic profiling has identified increased expression of AKT and STAT signalling in the invasive cell lines, events that are also known to occur in primary disease [[26](#_ENREF_26)]. Similar studies also identified secreted biomarkers known to be involved in metastasis of non-invasive and invasive cells [[27](#_ENREF_27)]. The model has also proven useful in dissecting the role of poor prognostic biomarkers, such as BRMS1 and FSP1 *in vitro* [[22](#_ENREF_22),[28](#_ENREF_28)] and for the identification and functional assessment of novel biomarkers of progression from DCIS to invasive disease both using 3-Dimensional (3D) culture and *in vivo* models [[21](#_ENREF_21),[23](#_ENREF_23),[29](#_ENREF_29)].

Here we sought to i) define the genomic characteristics at base pair resolution, of the MCF10 breast cancer progression series of cell lines that are associated with different stages of progression ii) determine the enrichment of pathway alterations in progression from pre-invasive to invasive disease, iii) establish an *in vitro* functional screening tool using cancer cell line spheroids, which more accurately recapitulate *in vivo* models and iv) use this platform as biological proof of concept to identify potential driver genetic alterations of breast cancer progression.

**MATERIALS AND METHODS**

**Cell lines**

The isogenic MCF10 cell line series includes the initial untransformed normal cell line, MCF10A, the benign proliferation stages (MCF10AT1 and MCF10NeoT), the carcinoma *in situ* stage (MCF10DCIS.com) and the invasive carcinoma stages (MCF10CA1a cl1, MCF10CA1d cl1 and MCF10CA1h). Cell lines were kindly provided by The Barbara Ann Karmanos Cancer Institute (Detroit, MI, USA), except for MCF10A cells that were purchased from The American Type Culture Collection (LGC), and MCF10DCIS.com cells from Asterand, Inc. (Herts, UK). Cells were authenticated by short tandem repeat (STR) typing using the Geneprint10 Kit (Promega, UK) and routinely tested for mycoplasma infection using an ELISA-based test (MycoAlertTM Mycoplasma detection kit, Lonza, Basel, Switzerland). Cells were grown as described [[30](#_ENREF_30)] and in Supplementary methods.

**Nucleic acid isolation**

DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen, UK) and RNA was extracted using Trizol (Life Technologies) according to the manufacturer’s instructions. Nucleic acids were quantified using the Qubit Fluorometer assay (Life Technologies), and RNA integrity was defined using a Bioanalyzer (Agilent Technologies). All samples had an RNA integrity number (RIN) > 9.

**Exome sequencing**

Genomic DNA (1 μg) was subjected to DNA capture, using the Human All Exome V4 XT kit (Agilent, CA, USA), and sequenced on 50% of a lane on a Illumina HiSeq2500, to result in a minimum of 109X median depth of coverage. Paired-end reads in FASTQ format were aligned to the reference human genome build GRCh37 using Burrows-Wheeler Aligner (BWA) [[31](#_ENREF_31)]. Variants were identified using the Genome Analysis Toolkit v3 (GATK) [[32](#_ENREF_32)] and variant annotation performed according to GATK Best Practices recommendations using Refseq and excluding decoy sequences [[33](#_ENREF_33),[34](#_ENREF_34)]. Exome DNA sequencing was also performed using the Ion Torrent AmpliSeq technology (Life Technologies, Paisley UK), according to the manufacturer’s instructions (Supplementary methods), with median depth >100 for all samples. The Torrent Suite v4.0.2 pipeline (Life Technologies) was used to align raw reads and identify variants. Calls from the GATK where overlapped with calls from The Torrent Suite v4.0.2 pipeline to identify robust mutations. Candidate somatic mutations were called based on filtering of variants with minor allele frequencies >1% according to dbSNP build 132 and with <5 supporting reads. Mutations associated with progression in any cell line from MCF10neoT onwards were subsequently annotated based on calls by Strelka [[35](#_ENREF_35)] using MCF10As as the baseline comparator and manual review using the Integrative Genomics Viewer [[36](#_ENREF_36)] to rule out the presence of reads supporting a given mutation in the ‘negative’ cell lines. Variants were subsequently annotated using Annovar [[37](#_ENREF_37)]. Mutations were overlaid with annotated data from primary breast cancers from The Cancer Genome Atlas (TCGA) [[38](#_ENREF_38)] and subjected to functional prediction algorithms (Supplementary methods). A subset of variants taken forward for functional analysis were validated in all cell lines using Sanger Sequencing as described [[39](#_ENREF_39)].

**Whole genome sequencing**

Libraries for whole genome sequencing were prepared following the NEBNext Ultra DNA Library Preparation kit (New England Biolabs) from 1μg of DNA according to the manufacturer’s protocol. Whole genome sequencing FASTQ files were aligned to the human genome (hg19) using Burrows-Wheeler Aligner (BWA) [[40](#_ENREF_40)] and copy number variations were identified using the Patchwork [[41](#_ENREF_41)] and GISTIC algorithms [[42](#_ENREF_42)] as described in Supplementary methods. DNA was also subjected to high-resolution microarray comparative genomic hybridisation (aCGH) as previously described [[43](#_ENREF_43)] and in Supplementary methods.

**Paired-end massively parallel RNA sequencing**

RNA sequencing was performed using 100ng of ribosomal-depleted RNA from cell lines grown on plastic (2D and as spheroids) as described [[44](#_ENREF_44)] (See Supplementary methods). RNA sequencing FASTQ files were aligned to the human genome (GRCh37.73) using TopHat version 2.0.8b [[45](#_ENREF_45)]. Reads mapping to two or more locations were removed from the analysis. Differential gene expression analysis was performed using DESeq2, with an adjusted P-value cut-off of ≤ 0.01 [[46](#_ENREF_46)]. The gene expression of the pre-invasive cells, (MCF10A, MCF10AT1 and MCF10neoT) were compared with the invasive cells (MCF10Ca1a, MCF10Ca1d and MCF10Ca1h). MCF10DCIS.com were omitted from this analysis given that they form pre-invasive lesions *in vivo* that spontaneously become invasive [[47](#_ENREF_47)]. Fusion genes were identified using Chimerascan [[48](#_ENREF_48)] and deFuse [[49](#_ENREF_49)] algorithms. Pathway enrichment was performed using ConsensusPathDB [[50](#_ENREF_50)].

**RT-qPCR and Sanger sequencing validation**

Reverse transcription was performed with Superscript III (Invitrogen) using 500ng of RNA per reaction as described [[51](#_ENREF_51)] and see Supplementary methods. Sequences were visualised using 4Peaks (http://nucleobytes.com/4peaks/). In-frame fusion genes were quantitated in the cell line series using RT-qPCR and the relative abundance of the fusion transcript to β-actin mRNA (*ACTB*) was calculated using the delta-delta CT method. Primer sequences are listed in Supplementary Table S1.

**siRNA screen**

Genes were chosen to be screened using siGENOME smartpool siRNA (GEHealthcare) targeting wild-type genes in 96-well spheroid assays, based on either the presence of i) recurrent amplifications and homozygous deletions, or ii) non-synonymous coding mutations in the progression series. Alterations were chosen that were also present in primary tumours assessed from METABRIC [[52](#_ENREF_52)] and microarray comparative genomic hybridisation studies [[53-55](#_ENREF_53)] for copy number alterations and from TCGA and other published studies at a frequency >0.5% for somatic mutations [[56-60](#_ENREF_56)]. For amplifications and homozygous deletions, those that are either known drivers or predicted drivers (for amplifications) as assessed from a significant correlation of amplification with gene expression [[55](#_ENREF_55)] were selected. For mutations, those that are known to be drivers or predicted to be drivers from the prediction algorithm FATHMM [[61](#_ENREF_61)] were triaged for functional assessment.

**Three-dimensional spheroid cultures**

5000 cancer cells per well of a 96-well low attachment plate (Corning) were reverse-transfected with 37.5 nM of siGENOME smartpool siRNA (GEHealthcare) or siControls (positive (ubiquitin B) and negative (pool 1)) using Lullaby reagent (Oz biosciences) in 180 µl of cold culture medium as described [[62](#_ENREF_62)]. Spheroid area was calculated using the Celigo S (Nexcelom, MA, USA) and viability was measured using the CellTiter-Glo® assay (Promega, UK). Relative growth was calculated relative to siControl. Hits were scored as >1.2 for increased spheroid growth and <0.8 for reduced cell growth (see Supplementary methods).

**Transfections of mammalian cells on plastic**

2500 cancer cells per well of a 96-well plate (Greiner) were reverse-transfected with 37.5nM of siGENOME siRNA using Lullaby reagent (Oz biosciences) as described [[54](#_ENREF_54)] and see Supplementary methods.

**Immunohistochemistry of spheroid cultures**

Spheroids were grown for 7 d and fixed in 3.8% formaldehyde for 30 min, washed with PBS three times and stored at 4 °C. Spheroids were then pooled, dehydrated, embedded in paraffin and sectioned. The spheroid sections were then de-paraffinized with xylene, rehydrated, microwaved and then incubated overnight with primary antibodies against Ki67, TP53 and pAKT (see Supplementary methods).

**Statistical analyses**

 P-values less than 0.05 (heteroscedastic, two-sided) were considered statistically significant for comparisons of the siRNA screen.

**Data availability**

Whole genome, exome and RNA-sequencing data have been deposited in the NCBI Sequence Read Archive under the accession PRJNA308098.

**RESULTS**

**Genomic alterations associated with breast cancer progression**

To better understand the role of genomic and transcriptomic alterations in breast cancer progression we performed whole exome, low depth whole genome and RNA-sequencing of the MCF10 progression series (Figure 1A) to comprehensively define the repertoire of mutations, copy number alterations, expressed fusion genes and transcriptional alterations. Whole exome sequencing was performed using both capture and amplicon based sequencing at >100x depth. This identified 7275 coding non-synonymous variations (SNV’s) in MCF10A; 7327 in MCF10neoT; 7336 in MCF10AT1; 7364 in MCF10DCIS.com; 7354 in MCF10Ca1a; 7351 in MCF10Ca1d and 7358 in MCF10Ca1h. Taking MCF10A cells as the baseline, we identified mutations in 196 genes that were acquired in the malignant cell lines (i.e. not present in MCF10A non-malignant cells, Supplementary Table S2) including 64 genes that also occur in The Cancer Genome Atlas (TCGA) and other published DNA sequencing studies [[56-60](#_ENREF_56)] (Figure 1B). These included a *PIK3CA* hotspot mutation (H1047R) acquired in MCF10DCIS.com cells and maintained in the invasive cell lines MCF10Ca1a-1h (in agreement with previous reports [[63](#_ENREF_63)]) and novel convergent mutations in *TP53* in MCF10Ca1a and MCF10Ca1h cells. We next defined the presence of relevant breast cancer predicted driver gene mutations that were acquired in the malignant cells, by annotating the variants with a combination of functional prediction algorithms (see Materials and Methods) and the specific cancer driver prediction algorithm FATHMM [[61](#_ENREF_61)]. This analysis revealed 53 mutations that were predicted to disrupt protein function and seven predicted cancer driver mutations. These encompassed four predicted cancer driver mutations that were acquired from non-malignant MCF10A cells to malignant DCIS.com cells (*HRAS, EPHA7, MAP3K12, PCSK5*) and three that were acquired from MCF10DCIS.com cells to invasive cells (MCF10Ca1a-1h), (*PTPRD, TP53, VSP13A*) (Figure 1E, Supplementary Figure S1 and S2). Furthermore, 57% of all variants were expressed at the RNA-level, (Supplementary Table S2).

**Somatic copy number alterations associated with progression**

We used low depth (on average 7x (range 6-9x coverage) whole genome sequencing to characterise the repertoire of copy number alterations of cell lines within the progression series. Consistent with previous observations [[24](#_ENREF_24),[63](#_ENREF_63)], MCF10A cells have high-level gains of 1q, gains of 5q, 8q, 19q and 20q and homozygous deletion of 9p encompassing *CDKN2A/B* (Supplementary Figure S3). Indeed, the other cell lines are comparable, with high-level focal amplification of 8q24.21, encompassing *MYC*, 10q22.1-q22.2 and 17p11.2 (Figure 1D, Supplementary Table S3). They do not have gain of 1q and therefore are probably derived from a clone of the parental line that had normal 1q (Figure 1C). Interestingly, MCF10DCIS.com cells had both the gain of 1q seen in the parental MCF10A cells and the three focal high-level amplifications. A number of homozygous deletions were acquired during progression including 8p23.1 (MCF10DCIS.com, MCF10Ca1a and MCF10Ca1d), 12p13.2 (MCF10AT1, MCF10DCIS.com and MCF10Ca1a) and 22q12.2 (MCF10neoT, MCF10AT1, MCF10DCIS.com, MCF10Ca1a and MCF10Ca1d) (Figure 1C, Supplementary Figure S3 and S4 and Supplementary Table S3). In addition acquisition of a focal intragenic homozygous deletion of *RUNX1* (MCF10DCIS.com, MCF10Ca1a and MCF10Ca1d) was identified (in agreement with previous reports [[63](#_ENREF_63)]).

**Fusion gene transcripts associated with progression**

Previous studies have reported that breast cancers can show extensive large-scale genomic rearrangements [[64](#_ENREF_64)] and have documented the presence of expressed fusion genes that drive the malignant phenotype of the cells and present therapeutic opportunities [[43](#_ENREF_43),[65](#_ENREF_65)]. RNA-sequencing analysis of the MCF10 progression series identified expressed fusion genes in MCF10DCIS.com (n=1), MCF10Ca1d (n=1) and MCF10Ca1h (n=2) that were identified by both deFUSE [[49](#_ENREF_49)] and Chimerascan [[48](#_ENREF_48)] fusion gene detection algorithms (Supplementary Table S4). These included two fusion transcripts predicted to result in novel functional proteins (i.e. in-frame) that were not present in MCF10A cells, namely an inter-chromosomal fusion involving *RAB3GAP1-HRAS*, detected in MCF10DCIS.com and MCF10Ca1d cells, and an intra-chromosomal fusion on chromosome 19q involving *UBA2-PDCD2L* in MCF10Ca1h cells (Figure 2A,B). Validation of the fusion transcripts using RT-qPCR and Sanger sequencing demonstrated that the in-frame *RAB3GAP1-HRAS* fusion was present in all cell lines that had been subjected to HRAS transformation (i.e. from MCF10AT1 onwards), whereas *UBA2-PDCD2L* was only seen in MCF10Ca1h cells (Figure 2C and D, Supplementary Table S4). Neither fusion was detected in the control cell line, MCF7. Furthermore, the levels of *RAB3GAP1-HRAS* transcript expression increased from MCF10neoT cells across the progression series with MCF10Ca1d cells showing the highest expression. This observation mirrored *HRAS* gene expression levels detected in the RNA-sequencing data (Figure 2E), suggesting that the differences in HRAS expression may be attributed to the presence of the fusion gene. Interestingly, the reciprocal fusion of *HRAS-RAB3GAP1* was detected in MCF10DCIS.com cells, however, this was not predicted to result in a functional protein. Mining of the TCGA Fusion gene Data Portal (<http://54.84.12.177/PanCanFusV2/>) [[66](#_ENREF_66)] and other published fusion data-sets in breast cancer [[43](#_ENREF_43),[64](#_ENREF_64),[65](#_ENREF_65)] identified two additional in-frame fusion genes involving *RAP3GAP1* in breast cancer (*RAB3GAP1-ACMSD* and *RAB3GAP1-MAP4K3*). An in-frame *HRAS* fusion gene was identified in a head and neck primary tumour (*RNH1-HRAS*) that leads to increased levels of HRAS expression [[66](#_ENREF_66)], however, no additional *HRAS* fusion genes were detected in primary breast cancers. An out-of-frame *UBA2-PDCD2L* fusion was detected in a primary ovarian cancer, but none was observed in breast cancer.

**Pathway alterations associated with breast cancer progression**

We next sought to assess the differences in gene expression during progression from pre-invasive to invasive disease. Differential gene expression of pre-invasive cell lines (MCF10A, MCF10AT1, MCF10NeoT) and invasive cell lines (MCF10CA1a, MCF10Ca1d, MCF10Ca1h) identified 236 significantly differentially expressed genes (p-value FDR <0.01, DEseq2), (Figure 3A, Supplementary Table S5). These genes were enriched in pathways involved in platelet amyloid precursor protein processing, senescence, autophagy and arachidonic acid metabolism (Figure 3B, Supplementary Table S6). Previous studies have demonstrated that the MCF10 progression series behave differently when grown in 3D culture and provide a useful model for studying driver alterations associated with oncogenic transformation [[67](#_ENREF_67),[68](#_ENREF_68)] and disease progression [[69](#_ENREF_69),[70](#_ENREF_70)]. Indeed, cell lines from the progression series formed spheroids, displayed good growth kinetics and positive histological staining of pro-proliferative markers, Ki67 and phospho-AKT (Supplementary Figure S5). To further evaluate functional pathways that may be dysregulated in breast cancer progression, in cells grown in more *in vivo* like conditions [[62](#_ENREF_62)], we performed RNA-sequencing of the series of cell lines grown as 3D spheroids. This analysis identified 1022 genes that were differentially expressed between pre-invasive and invasive cell lines (Supplementary Table S5). Functional annotation of these genes identified significant over-representation of pathways involved in nuclear receptor signalling, EGFR signalling, ErbB receptor signalling, FGFR signalling, signal transduction, integrin signalling and extracellular matrix organisation (Figure 3A,B and Supplementary Table S6). These findings indicate that more cancer-relevant pathways are active when cells are grown in a 3D environment, possibly reflecting the way the cells were selected for *in vivo* when they were generated [[19](#_ENREF_19)].

**Functional characterisation of driver alterations upon progression**

Given our observations that when grown in spheroid cultures, the MCF10 cell line series show enrichment of cancer-relevant pathways associated with progression to invasive disease, we sought to functionally test which genomic alterations (amplifications, homozygous deletions and mutations) that are also seen in primary breast cancers (Figure 3C and see Materials and methods) would be driving the growth of these cells. Cell lines were optimised for siRNA-mediated gene depletion where ablation of the tumour suppressor Phosphatase and tensin homolog (*PTEN*) and Ubiquitin B (*UBB*) resulted in increased and decreased spheroid growth relative to control siRNA, respectively (Supplementary Figure S5). A siRNA-based screen of 18 genes identified three that constitute potential driver events, namely *PIK3CA* (p=0.0485, *t*-test), *HRAS*, and *TP53* (p<0.0001, *t*-test) that when silenced decreased spheroid growth and were associated with genomic status (Figure 3D, Supplementary Table S7). De-convolution of the siRNA oligo pools identified that all of these genes were oncogenic drivers, resulting in decreased spheroid growth when silenced (Supplemental Figure S6). These included *PIK3CA* where cells with a H1047R activating mutation, showed selective dependency on *PIK3CA* silencing (Figure 4A). In addition, *PIK3CA* mutant cells were also selectively dependent on *AKT1* silencing (p=0.046, *t*-test), perhaps reflective of the subsequent increased AKT1 activation, (Figure 4A and Supplementary Figure S5 and S6), however this appeared to be an effect specific to cells grown as spheroids, and was not observed in traditional 2D culture (Figure 4B and Supplementary Table S7). Furthermore, the ER-negative breast cancer cell line BT20, which harbours a H1047R PIK3CA mutation, showed a similar effect (Figure 4B). Moreover, breast cancer cell line spheroids displayed dependency on PIK3CA according to their PIK3CA status with mutant MCF7 and T47D cells (harbouring E575K and H1047R PIK3CA mutations respectively) being sensitive to *PIK3CA* silencing while MDA-MB-231 cells (WT) showed no change in viability after *PIK3CA* silencing. It is tempting to posit that this is due to the maintenance of AKT activity under unfavourable conditions imparted by the spheroid architecture, as spatial AKT activity was observed in the pre-invasive cell lines, while stable and high P-AKT staining was observed in the invasive cell line spheroids that harboured the activating mutation in *PIK3CA* (Figure 4E).

Interestingly we observed two independent SNV’s in MCF10Ca1a and MCF10Ca1h in the DNA binding domain of TP53, suggestive of convergent evolution. *TP53* silencing in the progression series significantly correlated with smaller spheroid size in mutant cells, suggesting that these mutations are acting in an oncogenic manner (p=0.0051, *t*-test). Moreover, there was a significant dependency on TP53 associated with increased progression (pre-invasive versus invasive cells, p=0.0021, *t*-test) regardless of mutation status that appeared to correlate with increased nuclear accumulation of TP53 protein in these cells (Figure 4D,E). Of note, all cell lines showed sensitivity to MYC silencing, suggesting that cells are dependent on MYC transcriptional activity independent of amplification status (Figure 4D).

Given that MCF10A cells underwent HRAS transformation to produce subsequent cell lines, we tested whether cells would still be addicted to the oncogenic RAS signalling further along progression. Indeed, silencing of *HRAS* reduced spheroid growth of all cells subsequent to MCF10A (Figure 5A), however this association appeared to be significantly correlated with expression of the *RAP3GAP1-HRAS* fusion (r=-0.7857, p=0.0480, Spearman rank correlation), rather than on total *HRAS* expression (r=-0.5714, p=0.2, Spearman rank correlation) and in a similar manner to *PIK3CA* and *AKT1* seemed to be more specific to cells grown as spheroids (Supplementary Figure S5). Specific silencing of the *RAB3GAP1-HRAS* fusion however had no effect on spheroid growth (Figure 5A and B), perhaps indicative of the subclonal nature (as evidenced by the low percentage of the transcript involved in the fusion, i.e. isoform fraction) of the cells in which the fusion was detected from RNA-sequencing (Supplementary Table S4).

**DISCUSSION**

Here we have performed a comprehensive analysis of both the genomes (at base-pair resolution) and transcriptomes of the MCF10 cell line series that represent different stages of breast cancer progression when grown *in vivo* and demonstrated that these cell lines harbour relevant driver alterations seen in primary breast cancers, and represent a good model for studying breast cancer progression using *in vitro* spheroid models.

Overall, the patterns of genomic copy number alterations are similar between the cell lines, however, key differences emerge, suggestive of subclonal selection from the parental MCF10A cells. In particular, at base-pair resolution, the number of mutations varied across cell lines, with a number of key driver mutations being selected for at different stages of progression. These included a *PIK3CA* hotspot mutation in MCF10DCIS.com cells that leads to increased AKT signalling and *TP53* mutations in the more aggressive invasive cell lines MCF10Ca1a and MCF10Ca1h [[71](#_ENREF_71)], evidenced by increased nuclear accumulation of TP53 protein in these cells. We identified a number of mutations that were clonally selected through progression for which the allele fraction altered in the different cell lines. It may be the case that such alterations are merely passengers (i.e. do not confer a selective advantage to the cells), however, they may provide a growth advantage at different stages of progression, which is in agreement with recent studies from triple-negative breast cancers, where *bona fide* driver alterations have been shown to be subclonal and heterogeneously distributed [[59](#_ENREF_59)]. At the copy number level, focal high-level *MYC* amplification was acquired in the malignant cell lines as previously reported [[63](#_ENREF_63)], however it was not seen in MCF10A cells, which harboured gain of the entire arm of 8q. This finding is in agreement with other reports that find gain of *MYC* to be an initiating event in this cell line panel, rather than focal amplification [[72](#_ENREF_72)]. Indeed, *MYC* amplification has been associated with a poor prognosis [[73](#_ENREF_73),[74](#_ENREF_74)] and is often acquired in metastatic disease [[75](#_ENREF_75),[76](#_ENREF_76)]. All cells in the progression series though appeared to be sensitive to *MYC* silencing. Although the majority of the cell lines appeared to be derived from a clone lacking 1q gain, presence of 1q gain in MCF10DCIS.com may alternatively be a result of an iso-chromosome 1q being lost in culture.

Consistent with previous observations that the MCF10 progression series behave differently when grown in 3D culture [[69](#_ENREF_69),[70](#_ENREF_70)], we found a number of distinct differentially regulated pathways associated with progression when cells were grown in spheroids compared to traditional 2D culture, perhaps reflecting the nature of the nutrient and oxygen gradients in these models [[62](#_ENREF_62)]. Indeed, functional assessment of recurrent alterations identified oncogenic dependencies that were only observed when assessed in spheroid models, including a selective dependency on PIK3CA signalling in cells harbouring a H1047R mutation that was corroborated in additional breast cancer cells harbouring the H1047R mutation. Indeed, the H1047R mutation has been shown to promote metabolic adaption by increasing *de novo* lipogenesis [[77](#_ENREF_77)], a feature observed in aggressive cancers.

Through exome sequencing, we identified independent non-synonymous coding mutations in *TP53* in the MCF10Ca1a and MCF10Ca1h cell lines. Consistent with observations that *TP53* mutations can be late events in breast cancer progression [[59](#_ENREF_59)] and are associated with a poor prognosis [[78](#_ENREF_78)], it has been shown that these sub-lines can spontaneously metastasise when grown *in vivo* [[19](#_ENREF_19)]. Interestingly in all the invasive cells (MCF10Ca1a-1h), increased nuclear TP53 protein accumulation was observed, which correlated with sensitivity to *TP53* silencing suggesting TP53 dysregulation is associated with increased cellular invasiveness, and an oncogenic dependency in this model.

In addition to the identification of mutations associated with progression, we also identified two in-frame fusion genes in the cell line series. These included an *HRAS* fusion that was acquired in MCF10neoT cells, which were transformed by oncogenic HRAS, and was maintained in all subsequent cell lines. This fusion gene joins the promoter of *RAB3GAP1*, a GTPase-activating protein, to exon 3 of *HRAS*. Whilst interesting to speculate this fusion gene would also lead to selective HRAS dependency, given an observed correlation of HRAS oncogenic dependency and expression of the fusion gene, we observed no effect on spheroid growth with selective inhibition of the fusion gene. This may be due to the fact that the relative fraction of fusion transcript compared to wildtype transcript represents around 1% of all *HRAS* reads. As no additional *HRAS* fusion genes were observed from re-analysis of published RNA-sequencing data, this fusion most likely represents a consequence of HRAS v12 transformation.

Our study, although comprehensive, is not without limitations. *HRAS* mutation is not a common genetic alteration in human breast cancer, and thus the cell line series model might not accurately reflect the tumorigenic process in human breast cancers. This is exemplified by the identification of a fusion gene involving *HRAS* in the model and the lack of such fusion genes in primary breast cancer. Whilst exome sequencing identified acquisition of mutations in the malignant cells, we cannot rule out that these are present at very low subclonal populations in the parental MCF10A cells, given we did not perform high-depth targeted re-sequencing. Nevertheless, through exome sequencing with an average depth of 100x, we observed clonal selection of alterations across different cell lines, suggesting that MCF10A cells are oligoclonal. Whilst our copy number data support this, the low depth of coverage may also limit the detection of subclonal events. Our triage of genomic alterations for functional assessment mainly identified mutational events and homozygous deletions rather than amplifications that were representative of primary breast cancers. This may be due to our triage strategy, however, it is known that in general TNBCs lack many recurrent amplification events [[59](#_ENREF_59)]. Moreover, genomic alterations tested that did not impart a difference in spheroid growth may score in additional assays and may warrant further testing. In addition, functional assessment of differentially expressed genes may provide further insights into the drivers of progression in this model.

In conclusion, comprehensive characterisation of the MCF10 isogenic progression series has identified a number of driver alterations that are associated with progression from pre-invasive to invasive cellular phenotypes that model genomic alterations seen in primary breast cancer. Moreover, more accurate modelling of the *in vivo* tumour environment using 3D culture methods allows the validation of founder (HRAS transformation) and acquired (*PIK3CA* and *TP53* mutations) events that would not have been appreciated using traditional techniques. The MCF10 progression series therefore represents a good model to dissect potential biomarkers and evaluation of therapeutic targets involved in the progression of breast cancer.

**ACKNOWLEDGEMENTS**

This study was funded by Breast Cancer Now. RN is the recipient of a Breast Cancer Now Career Development Fellowship (2011MaySF01).

**AUTHOR CONTRIBUTIONS**

RN conceived the study. KB and GF provided materials. BP, PTW, SV, FD and RN carried out the experiments. SLM, JC, HB and AG performed the bioinformatics analysis. SLM, BP, PH, CJL and RN discussed and interpreted the results. SLM, BP, CJL and RN wrote the first draft. All authors read and approved the final manuscript.

**REFERENCES**

1. Cowell CF, Weigelt B, Sakr RA*, et al.* Progression from ductal carcinoma in situ to invasive breast cancer: revisited. *Mol Oncol* 2013; **7**: 859-869.

2. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M*, et al.* Breast cancer precursors revisited: molecular features and progression pathways. *Histopathology* 2010; **57**: 171-192.

3. Ma XJ, Dahiya S, Richardson E*, et al.* Gene expression profiling of the tumor microenvironment during breast cancer progression. *Breast Cancer Res* 2009; **11**: R7.

4. Simpson PT, Reis-Filho JS, Gale T*, et al.* Molecular evolution of breast cancer. *J Pathol* 2005; **205**: 248-254.

5. Vargas AC, McCart Reed AE, Waddell N*, et al.* Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. *Breast Cancer Res Treat* 2012; **135**: 153-165.

6. Simpson PT, Gale T, Reis-Filho JS*, et al.* Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. *Am J Surg Pathol* 2005; **29**: 734-746.

7. Fleischer T, Frigessi A, Johnson KC*, et al.* Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. *Genome Biol* 2014; **15**: 435.

8. Vincent-Salomon A, Lucchesi C, Gruel N*, et al.* Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. *Clin Cancer Res* 2008; **14**: 1956-1965.

9. Hernandez L, Wilkerson PM, Lambros MB*, et al.* Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. *J Pathol* 2012; **227**: 42-52.

10. Heselmeyer-Haddad K, Berroa Garcia LY, Bradley A*, et al.* Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. *Am J Pathol* 2012; **181**: 1807-1822.

11. Lodillinsky C, Infante E, Guichard A*, et al.* p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. *Oncogene* 2015.

12. Osuala KO, Sameni M, Shah S*, et al.* Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. *BMC Cancer* 2015; **15**: 584.

13. Allen MD, Marshall JF, Jones JL. alphavbeta6 Expression in myoepithelial cells: a novel marker for predicting DCIS progression with therapeutic potential. *Cancer Res* 2014; **74**: 5942-5947.

14. Soule HD, Maloney TM, Wolman SR*, et al.* Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. *Cancer Res* 1990; **50**: 6075-6086.

15. Miller FR, Soule HD, Tait L*, et al.* Xenograft model of progressive human proliferative breast disease. *J Natl Cancer Inst* 1993; **85**: 1725-1732.

16. Dawson PJ, Wolman SR, Tait L*, et al.* MCF10AT: a model for the evolution of cancer from proliferative breast disease. *Am J Pathol* 1996; **148**: 313-319.

17. Miller FR, Santner SJ, Tait L*, et al.* MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. *J Natl Cancer Inst* 2000; **92**: 1185-1186.

18. Strickland LB, Dawson PJ, Santner SJ*, et al.* Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. *Breast Cancer Res Treat* 2000; **64**: 235-240.

19. Santner SJ, Dawson PJ, Tait L*, et al.* Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. *Breast Cancer Res Treat* 2001; **65**: 101-110.

20. Buchanan NS, Zhao J, Zhu K*, et al.* Differential expression of acidic proteins with progression in the MCF10 model of human breast disease. *Int J Oncol* 2007; **31**: 941-949.

21. Elsarraj HS, Hong Y, Valdez KE*, et al.* Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. *Breast Cancer Res* 2015; **17**: 128.

22. Hurst DR, Xie Y, Edmonds MD*, et al.* Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. *Clin Exp Metastasis* 2009; **26**: 89-96.

23. Kaur H, Mao S, Li Q*, et al.* RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. *PLoS One* 2012; **7**: e50249.

24. Marella NV, Malyavantham KS, Wang J*, et al.* Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. *Cancer Res* 2009; **69**: 5946-5953.

25. Rhee DK, Park SH, Jang YK. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. *Genomics* 2008; **92**: 419-428.

26. So JY, Lee HJ, Kramata P*, et al.* Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model. *Mol Cell Pharmacol* 2012; **4**: 31-40.

27. Mbeunkui F, Metge BJ, Shevde LA*, et al.* Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. *J Proteome Res* 2007; **6**: 2993-3002.

28. Andersen K, Mori H, Fata J*, et al.* The metastasis-promoting protein S100A4 regulates mammary branching morphogenesis. *Dev Biol* 2011; **352**: 181-190.

29. Casbas-Hernandez P, D'Arcy M, Roman-Perez E*, et al.* Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. *Breast Cancer Res* 2013; **15**: R82.

30. Miller FR. Models of progression spanning preneoplasia and metastasis: the human MCF10AneoT.TGn series and a panel of mouse mammary tumor subpopulations. *Cancer Treat Res* 1996; **83**: 243-263.

31. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25**: 1754-1760.

32. McKenna A, Hanna M, Banks E*, et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**: 1297-1303.

33. DePristo MA, Banks E, Poplin R*, et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011; **43**: 491-498.

34. Van der Auwera GA, Carneiro MO, Hartl C*, et al.* From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* 2013; **11**: 11 10 11-11 10 33.

35. Saunders CT, Wong WS, Swamy S*, et al.* Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. *Bioinformatics* 2012; **28**: 1811-1817.

36. Robinson JT, Thorvaldsdottir H, Winckler W*, et al.* Integrative genomics viewer. *Nat Biotechnol* 2011; **29**: 24-26.

37. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**: e164.

38. Network T. Comprehensive molecular portraits of human breast tumours. *Nature* 2012; **490**: 61-70.

39. Natrajan R, Mackay A, Lambros MB*, et al.* A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *J Pathol* 2012; **227**: 29-41.

40. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 2010; **26**: 589-595.

41. Mayrhofer M, DiLorenzo S, Isaksson A. Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue. *Genome Biol* 2013; **14**: R24.

42. Mermel CH, Schumacher SE, Hill B*, et al.* GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol* 2011; **12**: R41.

43. Natrajan R, Wilkerson PM, Marchio C*, et al.* Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. *J Pathol* 2014; **232**: 553-565.

44. Maguire SL, Leonidou A, Wai P*, et al.* SF3B1 mutations constitute a novel therapeutic target in breast cancer. *J Pathol* 2015; **235**: 571-580.

45. Trapnell C, Roberts A, Goff L*, et al.* Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 2012; **7**: 562-578.

46. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol* 2010; **11**: R106.

47. Valdez KE, Fan F, Smith W*, et al.* Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. *J Pathol* 2011; **225**: 565-573.

48. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. *Bioinformatics* 2011; **27**: 2903-2904.

49. McPherson A, Hormozdiari F, Zayed A*, et al.* deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. *PLoS Comput Biol* 2011; **7**: e1001138.

50. Kamburov A, Pentchev K, Galicka H*, et al.* ConsensusPathDB: toward a more complete picture of cell biology. *Nucleic Acids Res* 2011; **39**: D712-717.

51. Natrajan R, Wilkerson PM, Marchio C*, et al.* Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. *J Pathol* 2014.

52. Curtis C, Shah SP, Chin SF*, et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 2012; **486**: 346-352.

53. Natrajan R, Lambros MB, Rodriguez-Pinilla SM*, et al.* Tiling path genomic profiling of grade 3 invasive ductal breast cancers. *Clin Cancer Res* 2009; **15**: 2711-2722.

54. Natrajan R, Mackay A, Wilkerson PM*, et al.* Functional characterization of the 19q12 amplicon in grade III breast cancers. *Breast Cancer Res* 2012; **14**: R53.

55. Natrajan R, Weigelt B, Mackay A*, et al.* An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. *Breast Cancer Res Treat* 2010; **121**: 575-589.

56. Ellis MJ, Ding L, Shen D*, et al.* Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature* 2012; **486**: 353-360.

57. Nik-Zainal S, Alexandrov LB, Wedge DC*, et al.* Mutational processes molding the genomes of 21 breast cancers. *Cell* 2012; **149**: 979-993.

58. Nik-Zainal S, Van Loo P, Wedge DC*, et al.* The life history of 21 breast cancers. *Cell* 2012; **149**: 994-1007.

59. Shah SP, Roth A, Goya R*, et al.* The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* 2012; **486**: 395-399.

60. Stephens PJ, Tarpey PS, Davies H*, et al.* The landscape of cancer genes and mutational processes in breast cancer. *Nature* 2012; **486**: 400-404.

61. Shihab HA, Gough J, Cooper DN*, et al.* Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum Mutat* 2013; **34**: 57-65.

62. Schug ZT, Peck B, Jones DT*, et al.* Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. *Cancer Cell* 2015; **27**: 57-71.

63. Kadota M, Yang HH, Gomez B*, et al.* Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. *PLoS One* 2010; **5**: e9201.

64. Stephens PJ, McBride DJ, Lin ML*, et al.* Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature* 2009; **462**: 1005-1010.

65. Robinson DR, Kalyana-Sundaram S, Wu YM*, et al.* Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. *Nat Med* 2011; **17**: 1646-1651.

66. Yoshihara K, Wang Q, Torres-Garcia W*, et al.* The landscape and therapeutic relevance of cancer-associated transcript fusions. *Oncogene* 2014.

67. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 2003; **30**: 256-268.

68. Debnath J, Mills KR, Collins NL*, et al.* The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. *Cell* 2002; **111**: 29-40.

69. Mullins SR, Sameni M, Blum G*, et al.* Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. *Biol Chem* 2012; **393**: 1405-1416.

70. Naber HP, Wiercinska E, Ten Dijke P*, et al.* Spheroid assay to measure TGF-beta-induced invasion. *J Vis Exp* 2011.

71. Peng X, Yun D, Christov K. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids. *Int J Oncol* 2004; **25**: 961-971.

72. Worsham MJ, Pals G, Schouten JP*, et al.* High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. *Breast Cancer Res Treat* 2006; **96**: 177-186.

73. Pereira CB, Leal MF, de Souza CR*, et al.* Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. *PLoS One* 2013; **8**: e60576.

74. Rodriguez-Pinilla SM, Jones RL, Lambros MB*, et al.* MYC amplification in breast cancer: a chromogenic in situ hybridisation study. *J Clin Pathol* 2007; **60**: 1017-1023.

75. Singhi AD, Cimino-Mathews A, Jenkins RB*, et al.* MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. *Mod Pathol* 2012; **25**: 378-387.

76. Wade MA, Sunter NJ, Fordham SE*, et al.* c-MYC is a radiosensitive locus in human breast cells. *Oncogene* 2015; **34**: 4985-4994.

77. Ricoult SJ, Yecies JL, Ben-Sahra I*, et al.* Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. *Oncogene* 2015.

78. Silwal-Pandit L, Vollan HK, Chin SF*, et al.* TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. *Clin Cancer Res* 2014; **20**: 3569-3580.

79. Futreal PA, Coin L, Marshall M*, et al.* A census of human cancer genes. *Nat Rev Cancer* 2004; **4**: 177-183.

**Figure Legends**

**Figure 1: Spectrum of acquired alterations in the MCF10 progression series.** (A) Diagrammatic representation of the generation of the MCF10 progression series. Non-invasive cells lines are highlighted in grey, DCIS.com cell are highlighted in green and invasive cell lines are highlighted in red. Circled numbers represent number of days cell lines were grown *in vivo* before replantation. (B) Matrix of somatic mutations identified acquired from MCF10A cells that also occur in The Cancer Genome Atlas (TCGA) breast cancer data. Mutations were classified according to membership of Cancer Gene Census (navy blue) [[79](#_ENREF_79)], the results of gene driver the prediction algorithm FATHMM (purple) [[61](#_ENREF_61)] and other prediction algorithms (grey), see methods. (C) Heatmap of gains (red) and losses (blue) identified from GISTIC. The genomic position is plotted along the x-axis and samples on the y-axis. Heatmap of focal (<10Mb) amplifications and homozygous deletions identified from GISTIC. The colour scale bar depicts homozygous deletions to amplifications (-2 to +2). Note the presence of focal amplification of *MYC* (8q24.21) acquired from MCF10neoT cells onwards. (D) Chromosome 8 plots of MCF10A, MCF10neoT and MCF10Ca1a cells of log2 normalised sequencing reads (y) plotted against base-pair position cross chromosome 8. Green represents an amplification log2 ratio >1.8. (E) Unrooted phylogenetic tree generated by neighbour joining of the MCF10 progression series based on variant data and whole arm chromosomal changes acquired from MCF10A. Driver mutations and chromosomal changes acquired are indicated in grey.

**Figure 2: Identification of expressed fusions in the MCF10 progression series.** (A) Cartoon representation of genomic location, orientation and architecture of expressed *RAB3GAP1-HRAS* fusion gene. Representative RNA-sequencing reads spanning the fusion are also displayed. The RT-PCR product was Sanger-sequenced; confirming the fusion junction, and a representative chromatogram from MCF10Ca1d cells is shown. (B) Cartoon representation of genomic location, orientation and architecture of expressed *UBA2-PDCD2L* fusion gene. Representative RNA-sequencing reads spanning the fusion are also displayed. The RT-PCR product was Sanger-sequenced; confirming the fusion junction, and a representative chromatogram from MCF10Ca1h cells is shown. (C) Bar plot showing relative expression of *RAB3GAP1-HRAS* fusion gene in the MCF10 progression series detected by qRT-PCR. (D) Bar plot showing relative expression of *UBA2-PDCD2L* fusion gene in the MCF10 progression series detected by qRT-PCR (E) Bar plot of normalised reads of *HRAS* in the MCF10 progression series from RNA-sequencing.

**Figure 3: Evaluation of pathways and driver alterations in spheroid cultures.** (A) Volcano plots showing the differentially expressed transcripts between pre-invasive and invasive cells from the MCF10 progression series cultured under both 2D and 3D conditions. Red = FDR p values <0.01. (B) Bar plot depicting the significantly over-represented pathways (ConsensusDb q value <0.01) from (A). (C) Schematic of gene selection for the siRNA screen. (D) Matched heatmaps of genomic status (mutation, amplification and homozygous deletion), results of spheroid growth after siRNA mediated silencing and gene expression. Relative spheroid growth is measured by the survival fraction of treated cells relative to siControl. Hits were triaged as a relative survival fraction compared to non-targeting control of <0.8 or >1.2. Gene expression is the log2 median centred normalised reads from the RNA-sequencing data.

**Figure 4: Functional validation of dependency on driver events in the MCF10 progression series.** (A) Progression series cell lines were reverse transfected with siRNAs against *PIK3CA*, *AKT1* and a non-targeting control. Spheroids were formed after 24 hours in low attachment plates and media was topped up every three days. After seven days spheroid viability was determined using Cell Titre Glo. (B) DCIS.com and BT20 cell lines were reverse transfected with siRNAs targeting *PIK3CA*, *UBB* and non-targeting control, under both 2D and 3D conditions. Media was topped up every three days. Viability was determined using Cell Titre Glo. Statistical comparisons were performed using Student’s *t*-test (\* p ≤0.05). (C) MDA-MB-231, MCF7 and T47D cell lines were reverse transfected with siRNAs targeting *PIK3CA*, *UBB* and non-targeting control, under 3D conditions. Media was topped up every three days and spheroid viability was determined using Cell Titre Glo. Statistical comparisons were performed using Student’s *t*-test (\* p ≤0.05). (D) Progression series cell lines were reverse transfected with siRNAs against *TP53*, *MYC* and a non-targeting control. Spheroids were formed after 24 hours in low attachment plates and media was topped up every three days. After seven days spheroid viability was determined using Cell Titre Glo. (E) Progression series were grown for seven days. Media was topped up every three days. On day seven, spheroids were fixed using formaldehyde, embedded, sectioned and stained for P-AKT (473) and total TP53. Representative images are shown. Scale bar = 100μm

**Figure 5: Functional validation of dependency on TP53 and HRAS in the MCF10 progression series.** (A) Progression series cell lines were reverse transfected with siRNAs against *HRAS*, *RAB3GAP1-HRAS* and a non-targeting control. Spheroids were formed after 24 h in low attachment plates and media was topped up every three days. Spheroid viability was determined using Cell Titer Glo. (B) MCF10Ca1a cells were reverse transfected with single and pooled siRNAs targeting *HRAS*, *RAB3GAP1-HRAS* and a non-targeting control for 72hrs. *HRAS*, *RAB3GAP1-HRAS* expression was determined using RT-qPCR. Expression was normalised to loading controls *B2M* and -actin. (*ACTB*)

**SUPPLEMENTARY INFORMATION ONLINE**

**The following supplementary information may be found in the online version of this article:**

**Figure S1.** Variant allele frequency plots of acquired mutations.

**Figure S2.** IGV screenshots of acquired mutations in the MCF10 progression series.

**Figure S3.** Copy number alterations in the MCF10 progression series.

**Figure S4.** Focal amplifications in the MCF10 progression series.

**Figure S5.** RNAi modulation of the isogenic MCF10 model in cancer cell line spheroids.

**Figure S6.** Oligo deconvolution in MCF10Ca1a cells in spheroids and on plastic.

**Table S1.** Details of primer sequences, siRNA sequences and RT-qPCR assays.

**Table S2.** Mutations identified in the MCF10 progression series.

**Table S3.** Gains and Losses and focal amplifications and deletions from GISTIC.

**Table S4.** Expressed fusion genes identified from RNA-sequencing of cell lines grown as spheroids identified by both DeFuse and Chimerascan algorithms.

**Table S5.** Differentially expressed genes between pre-invasive and invasive cells grown on plastic and as spheroids.

**Table S6.** Pathway analysis of differentially expressed genes between pre-invasive and invasive cell lines grown on plastic and as spheroids.

**Table S7.** Summary of siRNA screen in of cells grown as spheroids and on plastic.